.RESEARCH STUDY FEATURE.06 August 2024.
A large randomized controlled test with cisgender ladies highlights the obstacles of adherence to a daily oral preexposure prophylaxis regiment as well as demonstrates that twice-yearly injection of lenacapavir can sustain reliable HIV prevention levels over 6 months.